CA2334550A1 - Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme - Google Patents

Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme Download PDF

Info

Publication number
CA2334550A1
CA2334550A1 CA002334550A CA2334550A CA2334550A1 CA 2334550 A1 CA2334550 A1 CA 2334550A1 CA 002334550 A CA002334550 A CA 002334550A CA 2334550 A CA2334550 A CA 2334550A CA 2334550 A1 CA2334550 A1 CA 2334550A1
Authority
CA
Canada
Prior art keywords
apomorphine
androgen
administered
pro
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002334550A
Other languages
English (en)
Inventor
Michael A. Adams
Jeremy P.W. Heaton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University at Kingston
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2334550A1 publication Critical patent/CA2334550A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur un procédé de traitement des dysfonctionnements sexuels de la femme dont: les symptômes vasculogènes d'un engorgement vaginal retardé, une lubrification réduite du vagin, des rapports douloureux ou désagréables (dyspareunie), des sensations vaginales réduites, un orgasme vaginal atténué, des sensations clitoridiennes réduites, un orgasme clitoridien atténué, et de combat des douleurs vaginales, en stimulant la libération d'oxyde d'azote par le nerf pelvien périphérique. Le procédé consiste à administrer à la femme le nécessitant une dose à effet thérapeutique d'un composé agissant sur une voie mésencéphalique pour accroître le flux sanguin dans le lit vasculaire des artères iliaques, hypogastriques, et honteuses et stimuler la libération de NO par les cellules des nerfs NANC périphériques. Le composé préféré à cette fin est l'apomorphine ou l'un de ses sels, esters ou précurseurs pharmacocompatibles. Il est également possible d'associer l'apomorphine à une quantité potentialisante d'androgène, de préférence de testostérone, prise soit avant, soit avec l'apomorphine.
CA002334550A 1998-06-22 1999-06-21 Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme Abandoned CA2334550A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10298798A 1998-06-22 1998-06-22
US09/102,987 1998-06-22
PCT/CA1999/000567 WO1999066909A2 (fr) 1998-06-22 1999-06-21 Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme

Publications (1)

Publication Number Publication Date
CA2334550A1 true CA2334550A1 (fr) 1999-12-29

Family

ID=22292763

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002334550A Abandoned CA2334550A1 (fr) 1998-06-22 1999-06-21 Procede et compositions pour le traitement ou l'amelioration des dysfonctionnements sexuels de la femme

Country Status (7)

Country Link
EP (1) EP1089736A2 (fr)
JP (1) JP2002518435A (fr)
AR (1) AR019694A1 (fr)
AU (1) AU4254799A (fr)
CA (1) CA2334550A1 (fr)
MX (1) MXPA01000275A (fr)
WO (1) WO1999066909A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0005797A (pt) * 2000-03-20 2001-10-16 Abbott Lab Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
US6506765B2 (en) * 2000-04-07 2003-01-14 Tap Pharmaceutical Products, Inc. Apomorphine derivatives and methods for their use
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
FI20002756A0 (fi) * 2000-12-15 2000-12-15 Orion Yhtymae Oyj Uusi hoitomenetelmä
IL157734A0 (en) 2001-03-06 2004-03-28 Cellegy Pharma Inc Pharmaceutical compositions for the treatment of urogenital disorders
US20030022875A1 (en) * 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
GB0204919D0 (en) * 2002-03-01 2002-04-17 Cst Medical Ltd Treatment of female sexual dysfunction
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
DK349185A (da) * 1984-08-02 1986-02-03 Lilly Co Eli Octahydro-oxazolo(4,5-g) quinolin-forbindelser og fremgangsmaade til fremstilling heraf
US4640921A (en) * 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
WO1993023035A2 (fr) * 1992-05-18 1993-11-25 Smithkline Beecham Plc Emploi de derives d'indolone dans le traitement de troubles de la memoire, du dysfonctionnement sexuel et de la maladie de parkinson
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction

Also Published As

Publication number Publication date
AR019694A1 (es) 2002-03-13
AU4254799A (en) 2000-01-10
MXPA01000275A (es) 2002-04-24
WO1999066909A3 (fr) 2000-06-29
WO1999066909A2 (fr) 1999-12-29
JP2002518435A (ja) 2002-06-25
EP1089736A2 (fr) 2001-04-11

Similar Documents

Publication Publication Date Title
US6756407B2 (en) Method and compositions for the treatment or amelioration of female sexual dysfunction
TW550069B (en) Pharmaceutical compositions for use in treatment of female sexual dysfunction
US6291471B1 (en) Use of apomorphine for the treatment of organic erectile dysfunction in males
HUP0100121A2 (en) Pharmaceutical compositions for the treatment of conditions responsive to testosterone elevation
US20020002176A1 (en) Apomorphine derivatives and methods for their use
AU4254799A (en) Method and compositions for the treatment or amelioration of female sexual dysfunction
US20020165122A1 (en) Method and compositions for the treatment or amelioration of female sexual dysfunction
US6403605B1 (en) Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
MXPA01006105A (es) Uso de apomorfina en la elaboracion de un medicamento para el tratamiento de la disfuncion erectil organica en los hombres
AU2005201509A1 (en) Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males
CZ20002755A3 (cs) Způsob zlepšení ženské sexuální dysfunkce
HK1037517B (en) Use of apomorphine in the treatment of premature ejaculation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead